Kevin Soares, MD
Surgical Oncology · New York, NYNPI 1295977155
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,393 of the $10,160 with a category attached, or 92.5%. F. Hoffmann-la Roche AG accounts for 83.6% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $8,643, 6.1 times the $1,428 reported in 2019.
Across 18 payments — averaging $564.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$8K
- AstraZeneca$1K
- Intuitive Surgical$127
- Boston Scientific$88
- Olympus America Inc.$67
- Intera Oncology, Inc$21
What the payments were for
- Travel & lodging$9,39392%
- Food & beverage$7678%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 5 | $8,495 |
| AstraZeneca | 9 | $1,361 |
| Intuitive Surgical | 1 | $127 |
| Boston Scientific | 1 | $88 |
| Olympus America Inc. | 1 | $67 |
| Intera Oncology, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,160 in reported general payments places this provider in the 85th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 18 | $20,091 |
| Pantoprazole Sodium | 11 | $80 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in New York
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- George PlitasNew York$39K
- James ParkNew York$28K
- Michael LoweNew York$20K
- Scott HananNew York$15K
- Marcovalerio MelisNew York$12K
- Jennifer CracchioloNew York$9K
- Bert PetersenNew York$7K
- Paul SchmidtNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.